Burzynski Research Institute Inc's Cash & cash equivalent grew by 132.55 % in the Q3 2025 sequentially, while Current Liabilities decreased, this led to improvement in Burzynski Research Institute Inc's Quick Ratio to 0.03, Quick Ratio remained below Burzynski Research Institute Inc average.

Within In Vitro & In Vivo Diagnostic Substances industry 16 other companies have achieved higher Quick Ratio than Burzynski Research Institute Inc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 3662 to 4900.

Explain Quick Ratio?
How much Cash & cash equivalents BZYR�s has?
What are BZYR�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BZYR Quick Ratio	(Nov 30 2025) Q3	(Aug 31 2025) Q2	(May 31 2025) Q1	(Feb 28 2025) Q4	(Nov 30 2024) Q3
Y / Y Current Liabilities Change	215.84 %	-20.56 %	-44.72 %	54.86 %	-38.52 %
Y / Y Cash & cash equivalent Change	253.18 %	-23.44 %	176.43 %	-35.34 %	-32.86 %
Quick Ratio MRQ	0.03	0.01	0.01	0.02	0.03
BZYR's Total Ranking	# 4900	# 3662	# 3717	# 3128	# 782
Seq. Current Liabilities Change	-1.83 %	-0.47 %	67.68 %	92.77 %	-75.31 %
Seq. Cash & cash equivalent Change	132.55 %	13.4 %	-3.07 %	38.17 %	-49.59 %

Quick Ratio third quarter 2025 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 17
Healthcare Sector	# 997
Overall Market	# 4900

Quick Ratio Statistics
High	Average	Low
4.12	0.14	0
(Nov 30 2021)		(Nov 30 2013)

Financial Statements
Burzynski Research Institute Inc's Current Liabilities	$ 0 Millions	Visit BZYR's Balance sheet
Burzynski Research Institute Inc's Cash & cash equivalent	$ 0 Millions	Visit BZYR's Balance sheet
Source of BZYR's Sales		Visit BZYR's Sales by Geography

Cumulative Burzynski Research Institute Inc's Quick Ratio

BZYR's Quick Ratio for the trailling 12 Months

BZYR Quick Ratio	(Nov 30 2025) 12 Months	(Aug 31 2025) 12 Months	(May 31 2025) 12 Months	(Feb 28 2025) 12 Months	(Nov 30 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-4.99 %	-26.56 %	13.4 %	100.57 %	107.2 %
Y / Y Cash & cash equivalent TTM Growth	38.65 %	-14.03 %	-10.72 %	-21.1 %	1.3 %
Quick Ratio TTM	0.02	0.02	0.02	0.01	0.01
Total Ranking TTM	# 4497	#	#	#	#
Seq. Current Liabilities TTM Growth	23.02 %	-8.15 %	-20.39 %	5.62 %	-4.91 %
Seq. Cash & cash equivalent TTM Growth	48.32 %	-8.15 %	17.63 %	-13.47 %	-8.03 %

Quick ratio ranking by company, industry and sector >> Back to BZYR Financial Strength Comparisons >> Go to Compare BZYR Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the decrease in Current Liabilities in the Q3 2025 to $0.07 millions, cumulative Quick Ratio remained unchanged at 0.02 below the Burzynski Research Institute Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 16 other companies have achieved higher Quick Ratio than Burzynski Research Institute Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 0 to 4854.

Explain Quick Ratio?
How much Cash & cash equivalents BZYR�s has?
What are BZYR�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 17
Healthcare Sector	# 1012
Within the Market	# 4900

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.15	0.02	0
(Nov 30 2012)		(May 31 2020)

Companies with similar Quick Ratio in the quarter ending Nov 30 2025, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Nov 30 2025 MRQ Cash & cash equivalent	Nov 30 2025 MRQ Current Liabilities
Trinity Biotech Plc	0.04	$ 5.594 Millions	$ 141.209 Millions
Burzynski Research Institute Inc	0.03	$ 0.002 Millions	$ 0.070 Millions

Date modified: 2026-01-19T15:02:34+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.